Clinical significance of surface antigen of hepatitis B virus quantification in patients with hepatitis B cirrhosis related primary liver cancer

Abstract

Abstract: Objective To explore the clinical significance of surface antigen of hepatitis B virus quantification in patients with hepatitis B cirrhosis or with liver cirrhosis complicated with hepatocellular carcinoma(HCC) for early diagnosis of HBV related HCC. Methods 54 patients with hepatocellular carcinoma complicated by hepatitis B cirrhosis were enrolled into observation group, as well as 72 patients with simple hepatitis B cirrhosis were enrolled into control group. The serum HBsAg levels and HBV DNA loads were compared between the two groups. Results The serum HBsAg and HBV DNA in observation group were significantly decreased compared with that in control group(P<0.001). Conclusion The serum HBsAg were decreased in the course of Hepatitis B cirrhosis into hepatocellular carcinoma. The quantification of HBsAg was a predictor of hepatocarcinogenesis with clinical significance of early diagnosis.

Key words: Hepatocellular carcinoma(HCC), Hepatitis B cirrhosis , HBV related HCC, Surface antigen of hepatitis B virus(HBsAg )

XUE Hong-li, BAI Jin, SHAN Hong, QIN Li-li. Clinical significance of surface antigen of hepatitis B virus quantification in patients with hepatitis B cirrhosis related primary liver cancer[J]. Chinese Hepatolgy, 2020, 25(7): 743-745.

References

[1] Llovet JM,Zucman-Rossi J,Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers,2016,2:16018.
[2] Pisani P,Bray F,Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population .Int J Cancer ,2002,97:72-81.
[3] Locarnini S,Bowden S.Hepatitis B surface antigen quantification: not what it seems on the surface.Hepatology,2012,56:411-414.
[4] Larsson SB,Eilard A,Malmstr?m S,et al .HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers.Liver Int ,2014,34:e238-e245.
[5] Hadziyannis E,Laras A.Viral biomarkers in chronic HBeAg negative HBV infection .Genes(Basel),2018,9:469-489.
[6] 中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准.中华肝脏病杂志,2001,9:324-325.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版).临床肝胆病杂志,2015,31:1941-1960.
[8] El-Serag,H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology,2012,142:1264-1273.
[9] 吕峰,郜玉峰,饶建国,等.乙型肝炎后肝硬化并发原发性肝癌患者临床特征比较. 世界华人消化杂志,2015,23:2798-2804.
[10] Thompson AJ,Nguyen T,Iser D,et al.Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.Hepatology ,2010,51:1933-1944.
[11] Jaroszewicz J, Calle SB, Wursthorn K,et al.Hepatitis B surface antigen(HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection : a European perspective.Hepatology,2010.52:514-522.
[12] 裴颜祯,韩涛,马晓艳,等.HBsAg及HBV DNA定量水平在慢性乙型肝炎、肝硬化和肝癌患者中的变化.中华肝脏病杂志,2011,19:743-746.
[13] 杨晓萌,李勇忠,谭效勇,等.乙肝表面抗原定量、调节性T细胞在慢性乙型肝炎病毒感染中的研究进展.中国当代医药2019,26:24-27.
[14] 董爱爱,赵洁,贾建伟,等.HBsAg定量检测在慢性HBV感染患者肝脏储备功能评价中的作用.世界华人消化杂志,2012,20:3033-3036.
[15] Wong KH,Yuen MF,Poon RT,et al .Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. Hepatology,2006,45:553-559.
[16] 焦娇,郭意男,章国君,等.乙肝肝硬化进展原发性肝癌的危险因素研究.预防医学,2019,31:363-366.
[17] Ringelhan M,O’Connor T,Protzer U,et al.The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets . J Pathol,2015,235:355-367.
[18] Wu ZB,Cao H,Liu T ,et al .Dynamic expression profile of HBsAg according to hepatic parenchyma cells’volume at different liver fibrosis stages in the immune clearance phase.Zhonghua Gan Zang Bing Za Zhi,2012,20:742-745.
[19] 曾达武,董菁,陈丽红,等.免疫清除期慢性乙型肝炎患者血清HBsAg水平与肝组织炎症分级及纤维化分期的关系.中华肝脏病杂志,2012,20:746-750.
[20] 邓庆梅,高勇,何皖伟,等.原发性肝癌患者血清HBV标志物和HBV DNA测定的临床意义.实用肝脏病杂志,2012,15:414-416.
[21] 杨美荣,孟冬梅,方正亚,乙型肝炎后肝硬化并发原发性肝癌患者乙型肝炎病毒定量检测的临床意义.中国现代医学杂志,2019,29:76-79.